GLP1R and type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists (GLP1-RAs) or sodium–glucose cotransporter 2 inhibitors (SGLT2is) appear to improve renal outcome in patients with Type 2 diabetes (T2D).